People living in small-scale residential facilities vaccinated sooner by deploying Moderna as well as Pfizer/BioNTech Starting next week, vaccination for clients receiving care under the Long-Term Care Act, who are living in small-scale residential facilities without an institutional physician, will be expanded to the Pfizer/BioNTech vaccine and Moderna vaccine.
Lareb notes newly reported deaths shortly after vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a total of 15 reports so far regarding deaths shortly after receiving the COVID-19 vaccinations.
New research in GGD test lanes on spread of coronavirus SARS-CoV-2 RIVM is launching a survey-based study this week on risk factors for the coronavirus SARS-CoV-2. The participants in this study are people who get tested for COVID-19 in a GGD test lane.
80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
New variants disrupt plans In the past week, from 27 January to 2 February, 28,628 people in the Netherlands reportedly tested positive for COVID-19, a 20% decrease compared to the week of 20 to 26 January.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Joint Action CHRODIS PLUS: RIVM’s contribution to strengthening Health Promotion Within the Joint Action for the prevention and treatment of chronic diseases CHRODIS PLUS, RIVM has developed a set of recommendations for intersectoral cooperation to strengthen health promotion a
Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
Preparations for COVID-19 vaccinations now in progress RIVM is preparing for implementation of the coronavirus vaccinations. As soon as there is a safe and effective vaccine against the novel coronavirus, it will be quickly and carefully deployed to vaccinate the target groups.